C2I Genomics Inc., headquartered in the United States, is a pioneering force in the genomics industry, specialising in advanced genomic solutions for cancer detection and monitoring. Founded in 2020, the company has rapidly established itself as a leader in the field, leveraging cutting-edge technology to provide unique insights into tumour evolution and treatment response. C2I Genomics offers a range of innovative products and services, including comprehensive genomic profiling and liquid biopsy solutions, which are designed to enhance precision medicine. Their proprietary algorithms and data analytics capabilities set them apart, enabling healthcare providers to make informed decisions based on real-time genomic data. With a commitment to improving patient outcomes, C2I Genomics continues to make significant strides in the oncology landscape, positioning itself as a trusted partner in the fight against cancer.
We don't have data for C2I Genomics Inc., but we can show you information about their parent organization instead.
View parent company